Download Files:

1-Naphthohydroxamic acid

SKU HY-130538-10 mg Category Tags , ,

$65$750

Products Details

Product Description

– 1-Naphthohydroxamic acid (Compound 2) is a potent and selective HDAC8 inhibitor with an IC50 of 14 μM. 1-Naphthohydroxamic acid is more selectively for HDAC8 than class I HDAC1 and class II HDAC6 (IC50 >100 μM). 1-Naphthohydroxamic acid does not increase global histone H4 acetylation and also does not reduce total intracellular HDAC activity[1][2].1-Naphthohydroxamic acid can induce tubulin acetylation[3].

Web ID

– HY-130538

Storage Temperature

– -20°C, 3 years; 4°C, 2 years (Powder)

Shipping

– Room Temperature

Applications

– Cancer-programmed cell death

Molecular Formula

– C11H9NO2

References

– [1]Krennhrubec K, et al. Design and evaluation of ‘Linkerless’ hydroxamic acids as selective HDAC8 inhibitors. Bioorg Med Chem Lett. 2007 May 15;17(10):2874-8.|[2]Oehme I, et al. Histone deacetylase 8 in neuroblastoma tumorigenesis. Clin Cancer Res. 2009 Jan 1;15(1):91-9.

CAS Number

– 6953-61-3

Molecular Weight

– 187.19

Compound Purity

– 99.72

SMILES

– O=C(C1=C2C=CC=CC2=CC=C1)NO

Clinical Information

– No Development Reported

Research Area

– Cancer

Solubility

– DMSO : 125 mg/mL (ultrasonic)

Target

– HDAC

Isoform

– HDAC1;HDAC6;HDAC8

Pathway

– Cell Cycle/DNA Damage;Epigenetics

Product type

– Reference compound

Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.